Pharmaceuticals, Biotechnology and Life Sciences
Allergan and Heptares Therapeutics, the wholly-owned subsidiary of Sosei Group Corporation have entered into an agreement under which Allergan will license exclusive global rights to a broad portfolio of novel subtype-selective muscarinic receptor agonists in development for the treatment of major neurological disorders, including Alzheimer’s disease.
The U.S. Treasury Department took new steps on Monday to curb tax-avoiding corporate “inversions,” with the pending $160 billion merger of Pfizer Inc and Allergan Plc seen as a potential casualty.
Drugmaker Valeant Pharmaceuticals International Inc said on Monday its chief executive officer is leaving and billionaire investor William Ackman would join the board as it tries to clean up accounting problems and save its business.
Verona Pharma plc, the drug development company focused on first-in-class medicines to treat respiratory diseases, has provided a summary review of its 2015 performance.
Skyepharma has made an application to the UK Listing Authority (UKLA) and the London Stock Exchange for the listing of 1,100,000…
Sanofi and DiCE Molecules has announced a five-year global collaboration to discover potential new therapeutics for up to 12 targets that encompass all disease areas of strategic interest to Sanofi.
Drug maker Valeant faces debt default risk; shares plunge 50 percent
Sanofi welcomes new Executive Committee member
Sanofi and MSD/Merck in joint vaccines operations in Europe
Premaitha signs distribution agreement with GeNext in Russia